重组人血管内皮抑制素 (先声药业)(Recombinant Human Endostatin (Simcere)) - 药物靶点：VEGFR_在研适应症：非小细胞肺癌，恶性腹水，恶性胸腔积液_专利_临床

概要

基本信息

药物类型

重组蛋白

别名

Endostar、Endu、rh-endostatin

+ [2]

靶点

VEGFR

作用方式

拮抗剂

作用机制

VEGFR拮抗剂(血管内皮细胞生长因子受体拮抗剂)

治疗领域

肿瘤呼吸系统疾病其他疾病

在研适应症

非小细胞肺癌恶性腹水恶性胸腔积液

非在研适应症

晚期结直肠腺癌晚期肺腺癌晚期非小细胞肺癌+ [7]

原研机构

先聲藥業集團有限公司

在研机构

山东先声生物制药有限公司

非在研机构

江苏先声药业有限公司

权益机构-

最高研发阶段批准上市

首次获批日期

中国 (2005-09-12),

非小细胞肺癌

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 720094457

关联

91

项与重组人血管内皮抑制素 (先声药业) 相关的临床试验

NCT06965231

/ Recruiting临床2期IIT

Efficacy and Safety of Perioperative Toripalimab Combined With Recombinant Human Endostatin as Postoperative Adjuvant Therapy for Clinical Stage II Malignant Melanoma: A Multicenter, Single-Arm, Phase II Clinical Study

This is a Phase II clinical trial to evaluate the efficacy and safety of perioperative toripalimab (anti-PD-1) combined with recombinant human endostatin (Endostar) as postoperative adjuvant therapy in patients with clinical stage II cutaneous or acral malignant melanoma. The study aims to answer:
1. Does this combination improve the 2-year recurrence-free survival (2y-RFS) compared to historical data?
2. Is the treatment safe and tolerable for patients?
Participants will:
1. Receive 2 cycles of toripalimab before surgery (neoadjuvant therapy).
2. Undergo surgical removal of the tumor.
3. Post surgery, receive toripalimab every 2 weeks + Endostar (72-hour continuous infusion every 4 weeks) for up to 6 cycles (Endostar) or 11 cycles (toripalimab).
4. Be monitored for tumor recurrence, side effects, and survival for up to 2 years after treatment.
This is a single-arm, multicenter study involving 58 patients across several hospitals in China. Results will help determine if this combination could become a new standard adjuvant therapy for stage II melanoma.

开始日期2025-01-01

申办/合作机构

复旦大学

NCT06562673

/ Recruiting临床1/2期IIT

Efficacy and Safety of Intra-arterial Cisplatin Plus Anti-angiogenesis Inhibitor Rh-endostatin (Endostar) Combined With Systematic Chemotherapy in Osteosarcoma

The goal of this clinical trial is to learn the efficacy and safety of intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) combined with systematic chemotherapy in osteosarcoma. The main questions it aims to answer are:
* Is it safe when rh-endostatin and cisplatin are administered intra-arterially?
* Does intra-arterial cisplatin plus rh-endostatin increase the rate of tumor necrosis compared with traditional treatment?
Researchers will treat newly diagnosed osteosarcoma patients with systematic treatment and local treatment.
For systematic treatment, regular high-dose methotrexate and adriamycin will be administered intravenously.
For local treatment, rh-endostatin was administered intra-arterially with dosage of 150 mg for a 6-h continuous infusion; then cisplatin was administered intra-arterially at 120 mg/m2 as a 6-h continuous infusion.
Local treatment is conducted by insertion of a catheter percutaneously using the Seldinger technique through the brachial or femoral artery under local anesthesia.
Participants will:
• Receive local combined with systematic treatment once every 2-3 weeks for 2-4 cycles before surgery.

开始日期2024-12-01

申办/合作机构-

NCT06618391

/ Not yet recruiting临床2期IIT

Envafolimab and Recombinant Human Endostatin and Recombinant Human Adenovirus Type 5 Intratumor Local Injection Combined With Systemic Therapy in Patients With Advanced NSCLC :a Prospective, Exploratory Phase II Clinical Study Tudy

This study is a prospective, exploratory Phase II clinical study aimed at evaluating the safety and efficacy of Envafolimab and recombinant human endostatin and Recombinant Human Adenovirus Type 5 Intratumor local injection combined with systemic therapy in patients with locally advanced or advanced non-small cell lung cancer(NSCLC).

开始日期2024-10-08

申办/合作机构

河南省肿瘤医院

100 项与重组人血管内皮抑制素 (先声药业) 相关的临床结果

登录后查看更多信息

100 项与重组人血管内皮抑制素 (先声药业) 相关的转化医学

登录后查看更多信息

100 项与重组人血管内皮抑制素 (先声药业) 相关的专利（医药）

登录后查看更多信息

467

项与重组人血管内皮抑制素 (先声药业) 相关的文献（医药）

2025-12-31·CANCER BIOLOGY & THERAPY

Inhibitory effect of Endostar on HIF-1 with upregulation of MHC-I in lung cancer cells

Article

作者: Wang, Hai-Jing ; Wang, Jing-Na ; Zhao, Zhi-Wei ; Zhang, Yan-Min ; Zheng, Hong-Fei ; Zhao, Ming-Zhen

Endostar is a human recombinant endostatin which is an attractive anti-angiogenesis protein. Because inefficient antigen presenting MHC class I expression (which can be downregulated by HIF-1) is an important strategy for cancer immune evasion, besides its anti-angiogenesis effect, it remains unclear whether Endostar has an inhibitory effect on HIF-1 expression by upregulating MHC class I expression in cancer cells to facilitate immunotherapies, including PD-1/PD-L1 inhibitors. In this study, A549 and NCI-H1299 lung cancer cells were treated with Endostar (6.25 μg/ml, 12.5 μg/ml, and 25 μg/ml, respectively). HIF-1 expression was detected by Immunocytochemistry and Western blot. Proteins of the MHC class I α-heavy chain and β2 m light chain, STAT3 and pSTAT3 were detected by Western blot. The mRNAs of MHC class I α-heavy chain and β2 m light chain were detected by RT-qPCR. It was shown that decreased expression of HIF-1 and promotion of β2-microglobulin were observed after Endostar treatment. In addition, elevated levels of MHC class I α-heavy chain mRNA and protein, as well as downregulation of STAT3 and pSTAT3, were also observed following Endostar treatment. Endostar inhibited HIF-1 expression in A549 and NCI-H1299 lung cancer cells, upregulated expression of MHC class I α-heavy chain and β2 m light chain, with the upregulation of STAT3 and pSTAT3, suggesting involvement of STAT3 pathway. It is important because only in combination with MHC class I on target cells can tumor antigenic peptides be recognized by CD8+ CTLs which destroy target cells. However, MHC class I is frequently deficient in cancer cells.

2025-09-01·Therapeutic Advances in Medical Oncology

Efficacy of Endostar plus concurrent chemoradiotherapy in locally advanced cervical cancer: a multicenter, phase II randomized trial

Article

作者: Liao, Sihui ; Tang, Xiaobi ; Wang, Hongqian ; Liu, Meilian ; Jiang, Li ; Huang, Haixing ; Liu, Wenqi ; Ma, Shanshan ; Zhang, Yong ; Wu, Fang ; Luo, Zhanxiong

Background::

Cervical cancer remains the fourth most common malignant cancer in females and the fourth most common cause of mortality in women worldwide. Approximately 70% of new cases are diagnosed as locoregionally advanced cervical cancer (LACC), posing a significant threat to women’s health. Concurrent chemoradiotherapy (CCRT) is the established standard treatment for LACC. However, more than 30% of patients still experience local recurrence and distant metastasis. Improving treatment outcomes for LACC is a critical global objective.

Objective::

To investigate the safety and efficacy of adding Endostar to CCRT in patients with LACC.

Design::

This is a multicenter, open-label, randomized, controlled, phase II trial.

Methods::

A total of 120 patients were randomly allocated (1:1) to receive either CCRT alone (definitive radiotherapy plus cisplatin 40 mg/m 2 every week for 4–5 cycles) or CCRT plus Endostar, Endostar at a dose of 7.5 mg/m 2 /day, from 5 days before CCRT for 10 consecutive days every 15 days for four cycles).

Results::

The CCRT + E arm demonstrated a significantly higher complete response rate (CRR) compared to the CCRT arm (68.3% vs 35.0%, p = 0.001), while the overall response rate (ORR) was similarly in both arms (98.3% vs 100%, p = 1.000). The CCRT + E arm showed significantly improved distant metastasis-free survival (DMFS) (1-year: 91.6% vs 94.8%, 2-year: 82.3% vs 91.6%, 5-year: 67.0% vs 88.0% p = 0.029). No significant differences were found in overall survival (OS), progression-free survival (PFS), or locoregional recurrence-free survival (LRFS) ( p > 0.05). Multivariable analysis identified maximum tumor diameter >4 cm and failure to achieve CR as predictive factors of poor PFS, and maximum tumor diameter >4 cm and stage IIIA–IVA disease as poor prognostic factors for OS. According to the subgroup analysis, Endostar significantly improved the DMFS in cohorts of patients with squamous cell carcinoma ( p = 0.005), a maximum tumor diameter > 4 cm ( p = 0.011), and stage IB2 or IIA2–IIB disease ( p = 0.005). The rates of acute and late adverse reactions were similar in both arms ( p > 0.05), with no cardiac toxicity, hypertension, or grade 5 toxicity reported.

Conclusion::

The addition of Endostar to CCRT significantly enhanced tumor response (CRR) and reduced distant metastasis (DMFS) in LACC patients without increasing treatment toxicity, offering a promising therapeutic enhancement. Clinically, patients with squamous cell carcinoma, maximum tumor diameter > 4 cm, and International Federation of Gynecology and Obstetrics stage IB2 or IIA2–IIB disease derived particularly robust DMFS benefits from the combination regimen, suggesting they should be prioritized for this approach. Although the 5-year DMFS results are encouraging, validation in a larger phase III study and longer follow-up are warranted before considering this regimen as a new standard treatment modality for LACC.

Trial registration::

This trial was registered at ClinicalTrials.gov (NCT 03086681, registered 22 March 2017, https://clinicaltrials.gov/study/NCT03086681 .

2025-07-01·Journal of Thoracic Disease

Combining recombinant human endostatin with third-generation EGFR-TKIs in advanced EGFR-sensitive mutant non-small cell lung cancer

Article

作者: Wang, Fen ; Peng, Sujuan ; Tan, Aaron C ; Huang, Hongxiang ; Chen, Li ; Lu, Zhihui ; Kong, Ping ; Ding, Xinjing ; Song, Tiantian ; Chen, Jinhong ; Zhong, Peiyuan ; Zhu, Xie ; Xiao, Fang

Background:

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line options in advanced or metastatic EGFR mutant non-small cell lung cancer (NSCLC). This study aimed to compare the efficacy and safety of third generation EGFR-TKIs combined with recombinant human endostatin (Endostar) versus EGFR-TKIs alone in previously untreated advanced epidermal growth factor receptor (EGFR) mutant NSCLC patients.

Methods:

A total of 118 untreated advanced EGFR-sensitive-mutant NSCLC patients from a single center were retrospectively included in the study. Of the patients, 71 received third-generation EGFR-TKIs (the T group) and 47 received combination of Endostar and third-generation EGFR-TKIs therapy (the E + T group). Progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), the disease control rate (DCR), and adverse events (AEs) were evaluated.

Results:

Compared to the T group, the E + T group had a significantly higher ORR (91.5% vs. 77.5%; P=0.047), and improved PFS (20.2 vs. 17.6 months; P=0.002) and OS (41.5 vs. 33.8 months; P=0.04). However, there was no significant difference in the DCR between the two groups (97.9% vs. 97.2%; P>0.99). Multivariate analysis identified the Eastern Cooperative Oncology Group performance status (ECOG-PS) score, brain metastasis, EGFR co-mutation, and treatment regimen as independent prognostic factors. Subgroup analysis showed that the E + T group had greater clinical benefits for patients with ≥2 distant metastatic organs (P=0.01) and EGFR/TP53 co-mutations (P=0.01). The incidence of AEs of any level was higher in the E + T group than the T group (53.2% vs. 45.1%, P=0.39).

Conclusions:

In this real-world study, the combination of recombinant human endostatin and third-generation EGFR-TKIs significantly improved the ORR, PFS, and OS in previously untreated advanced EGFR-mutant NSCLC patients and thus represents a promising treatment option that requires further prospective evaluation.

79

项与重组人血管内皮抑制素 (先声药业) 相关的新闻（医药）

2025-11-05

·先声药业

SIM0237膀胱癌I期数据亮相2025国际泌尿外科学会年会口头报告

2025年10月29日-11月1日，第45届国际泌尿外科学会年会（SIU2025）在英国爱丁堡举行。先声药业集团旗下先声再明医药有限公司自主研发的PD-L1/IL-15双功能融合蛋白SIM0237用于非肌层浸润性膀胱癌（NMIBC）治疗的I期临床研究数据亮相大会口头报告。该研究的单药剂量递增阶段展现出良好的安全性、耐受性与抗肿瘤活性，引发国际泌尿医学界广泛关注。膀胱癌是常见的恶性肿瘤之一，其中非肌层浸润性膀胱癌(NMIBC)约占初诊患者的75%。NMIBC的主要治疗手段为局部手术切除及术后膀胱灌注化疗或卡介苗（BCG）治疗等，但依然存在较高的复发及进展风险。对于BCG无应答的NMIBC患者，目前标准治疗仍为根治性膀胱切除术，手术风险较高，并对患者生活质量有显著影响。 SIM0237是先声再明自主研发的PD-L1单抗与减活IL-15/IL-15Rα sushi融合蛋白。该分子通过结合PD-L1，阻断PD-1/PD-L1免疫抑制通路，同时通过IL-15激活免疫系统，发挥双功能协同抗肿瘤作用。SIM0237的IL-15端经过减活改造，可增加耐受性与暴露量。临床前研究显示，SIM0237在人膀胱癌异种移植模型中表现出显著的抗肿瘤活性。 SIM0237-102是一项开放标签、多中心I/II期研究。其单药剂量递增阶段纳入了17名对卡介苗无应答的高危NMIBC患者。三个剂量水平均显示出令人鼓舞的抗肿瘤活性：所有3名原位癌患者均达到完全缓解（CR），其中2名患者的CR状态到数据截止日期已分别维持6个月和12个月。另14名T1或高级别Ta期乳头状肿瘤患者中，中位无病生存期（DFS）尚未成熟，12个月DFS率为69.2%（95% CI, 37.3%-87.2%）。安全性方面，膀胱内灌注SIM0237在所有3个剂量水平均表现出良好的安全性特征，未出现任何剂量限制性毒性、药物相关严重不良事件或3级及以上药物相关不良事件。300毫克剂量被选为SIM0237单药治疗的推荐剂量。 SIM0237单药治疗NMIBC的剂量扩展部分以及SIM0237联合BCG的剂量递增部分正在进行中。单药剂量扩展部分结果提示SIM0237有望成为NMIBC的新型疗法，相关数据将于明年国际学术会议进一步披露。先声再明是先声药业集团旗下专注于肿瘤领域的生物医药公司，致力于以突破性治疗手段, 解决全球肿瘤领域巨大的未满足临床需求。先声再明已在中国成功推出多款创新产品，包含恩泽舒®、科赛拉®、恩维达®、恩度®、恩立妥®。先声再明以自主研发，与合作伙伴协同创新，为全球肿瘤患者提供潜在的变革性治疗方案。媒体联络：pr@zaiming.com 编辑 | 李逸玲审校 | 吴涛审核 | 汪咏钰

临床1期临床结果

2025-10-16

·先声药业

先声再明新型ADC候选药物SIM0505完成Ⅰ期临床美国首例患者入组

• 首例美国患者已完成给药，已有剂量组已观察到多重应答； • 多区域试验将加速概念验证，预计于2026年上半年获得数据。中国上海/美国马里兰州贝尔茨维尔，2025年10月16日——先声药业集团（2096.HK）旗下的抗肿瘤创新药公司先声再明与致力于癌症创新药开发的临床阶段美国生物制药公司NextCure, Inc.（Nasdaq：NXTC）今日宣布，SIM0505用于晚期实体瘤患者的Ⅰ期临床试验（NCT06792552）已完成首例美国患者给药。研究旨在评估该药物的安全性、耐受性、药代动力学及疗效。 SIM0505是由先声再明研发的一款靶向CDH6（钙粘蛋白-6或K-钙粘蛋白）的新型ADC。其独特的结合表位对肿瘤抗原的亲和力高于同类候选药物。SIM0505还采用了先声再明专有的TOPO异构酶1抑制剂(TOPOi)有效载荷，在具备强抗肿瘤活性的同时，也有较高的系统清除率，从而扩大治疗窗口。其Ⅰ期剂量递增研究在中国启动后，由NextCure扩展至美国，于中剂量组开始纳入美国患者，此后将在中美两国持续推进。NextCure已获得先声再明SIM0505在大中华区以外的全球独家许可。 NextCure首席医疗官Udayan Guha博士表示："我们对合作伙伴取得的重大进展感到欣慰，这使得我们能够以接近潜在临床推荐的剂量水平启动美国患者入组。根据现有数据，SIM0505的耐受性与安全性特征良好，相信其有潜力成为CDH6领域的领先疗法，期待加速推进当前试验并在2026年上半年得到概念验证数据。" 先声再明首席医学官汪咏钰博士表示："美国首例患者入组是SIM0505全球临床开发的重要里程碑。这标志着我们为中国及全球患者推进创新肿瘤治疗的又一重要步伐。" 先声再明是先声药业集团旗下专注于肿瘤领域的生物医药公司，致力于以突破性治疗手段, 解决全球肿瘤领域巨大的未满足临床需求。先声再明已在中国成功推出多款创新产品，包含恩泽舒®、科赛拉®、恩维达®、恩度®、恩立妥®。先声再明以自主研发，与合作伙伴协同创新，为全球肿瘤患者提供潜在的变革性治疗方案。媒体联络：pr@zaiming.com NextCure是美国一家临床阶段的生物制药公司，致力于通过采用具有差异化作用机制，包括抗体偶联药物开发创新疗法，用以治疗对现有疗法无反应或病情进展的癌症患者。NextCure专注于推进能够发挥其核心优势的疗法，这些优势包括对生物通路与生物标志物的深入理解、对细胞相互作用（包括肿瘤微环境中的相互作用）的研究，以及探索将这些相互作用转化为创新性治疗手段。http://www.nextcure.com 编辑 | 李逸玲审校 | 覃小恒审核 | 汪咏钰

临床1期抗体药物偶联物临床2期突破性疗法

2025-10-16

·ir.nextcure.com

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

First U.S. patient dosed at a mid-tier dose level where multiple responses have been observed Multi-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, and Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced that the first patient in the U.S. has been dosed with SIM0505 in the ongoing Phase 1 trial (NCT06792552), which is evaluating safety, tolerability, pharmacokinetics and efficacy in patients with advanced solid tumors. SIM0505 is a novel antibody drug conjugate directed to cadherin-6 (CDH6 ADC), featuring a proprietary topoisomerase 1 inhibitor (TOPOi) payload, designed for broad anti-tumor activity, high systemic clearance and an improved potential therapeutic window. NextCure has now expanded the ongoing Phase 1 dose escalation study, which was initiated in China, by enrolling patient(s) in the U.S. into a mid-tier dose level while dose escalation is currently advancing in China. NextCure acquired an exclusive global license, excluding Greater China, for SIM0505 from Simcere Zaiming. “We are pleased by the significant progress achieved by our partner, which has enabled us to start U.S. enrollment at doses within a therapeutic range where clinical responses have already been observed. Based on current data, SIM0505 has been well tolerated with a favorable safety profile,” said Udayan Guha, M.D., Ph.D., NextCure’s chief medical officer. “We believe that SIM0505 has the potential to become a leading ADC targeting CDH6. We look forward to accelerating the ongoing trial and presenting proof-of-concept clinical data in the first half of 2026.” “Enrollment of the first patient in the U.S. marks a significant milestone in global clinical development of SIM0505. This achievement reflects our ongoing commitment to advancing innovative oncology treatments for patients in China and worldwide,” said Yongyu Wang, M.D., Chief Medical Officer, Simcere Zaiming.” About NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. http://www.nextcure.com About Simcere Zaiming Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including COSELA®, Enweida®, Endostar®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners. NextCure’s Cautionary Statement Regarding Forward-Looking Statements Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “should,” “due,” “estimate,” “expect,” “intend,” “hope,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “target,” “towards,” “forward,” “later,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and not having any products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; NextCure’s ability to maintain listing of its common stock on the Nasdaq Global Select Market; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described under the heading “Risk Factors” in NextCure’s most recent Annual Report on Form 10-K and in NextCure’s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change. NextCure Investor Inquiries Timothy Mayer, Ph.D. NextCure, Inc. Chief Operating Officer (240) 762-6486 IR@nextcure.com Simcere Zaiming Contacts PR contacts: pr@zaiming.com IR contacts: ir@zaiming.com Source: NextCure

临床1期引进/卖出抗体药物偶联物临床申请

100 项与重组人血管内皮抑制素 (先声药业) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01	DB06423

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
非小细胞肺癌	中国	山东先声生物制药有限公司	2005-09-12

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
恶性腹水	临床3期	中国	山东先声生物制药有限公司	2021-07-21
恶性胸腔积液	临床3期	中国	山东先声生物制药有限公司	2021-07-21
局部晚期非小细胞肺癌	临床3期	中国	江苏先声药业有限公司	2018-08-01
晚期结直肠腺癌	临床3期	中国	江苏先声药业有限公司	2018-07-01
晚期肺腺癌	临床2期	中国	江苏先声药业有限公司	2012-03-01
脑转移瘤	临床2期	中国	江苏先声药业有限公司	2011-06-01
T细胞淋巴瘤	临床2期	中国	江苏先声药业有限公司	2011-06-01
食管癌	临床2期	中国	江苏先声药业有限公司	2011-05-01
局部晚期黑色素瘤	临床2期	中国	江苏先声药业有限公司	2008-08-01
转移性黑色素瘤	临床2期	中国	江苏先声药业有限公司	2008-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03086681 (Pubmed \| Ther Adv Med Oncol)	临床2期	局部晚期宫颈癌	120	Endostarcisplatin + Endostarcisplatin	鏇艱艱壓選選繭構簾鹽(構衊壓願選積顧糧選築) = 積憲廠顧醖夢夢鹹鑰獵遞蓋鬱壓構鏇構鹽廠製 (衊壓鏇憲衊淵網遞願選 ) 更多	积极	2025-09-01
				cisplatin	鏇艱艱壓選選繭構簾鹽(構衊壓願選積顧糧選築) = 襯窪壓齋餘製顧顧窪窪遞蓋鬱壓構鏇構鹽廠製 (衊壓鏇憲衊淵網遞願選 ) 更多
WCLC2024 人工标引	临床2期	非小细胞肺癌一线 driver gene-negative	29	EnvafolimabRh-endostatin	鹹壓衊積簾淵積鹽鹹鹹(壓積選顧選構構襯範鹹) = 壓衊顧鑰鹹憲顧廠糧膚壓衊簾網餘糧願淵醖窪 (膚網鹽艱鹹淵襯鏇膚積, 76.8 ~ 109.4) 更多	积极	2024-09-09
NCT05574998 (Pubmed)	临床2期	晚期非小细胞肺癌 serum carcinoembryonic antigen (CEA)	48	rh-endostatin + platinum with pemetrexed	窪獵窪艱鑰餘簾壓鏇憲(簾蓋廠襯選壓鑰蓋鏇獵) = 願觸觸範鑰衊鬱淵艱廠蓋願鹹範鹽衊願願夢繭 (選蓋鹽鹹壓選願鬱繭鑰, 3.8 ~ 9.1) 更多	积极	2024-06-01
				rh-endostatin + platinum with paclitaxel	窪獵窪艱鑰餘簾壓鏇憲(簾蓋廠襯選壓鑰蓋鏇獵) = 壓獵繭齋廠範憲蓋淵醖蓋願鹹範鹽衊願願夢繭 (選蓋鹽鹹壓選願鬱繭鑰, 3.8 ~ 9.1) 更多
NCT02907710 (phase III, ASCO2024) 人工标引	临床3期	晚期鼻咽癌	300	Endostar plus CCRT	鹽蓋顧顧選憲觸願憲繭(壓壓齋鬱膚遞膚積襯鏇) = 網餘積齋淵餘夢憲淵鑰襯糧觸積醖遞觸選製淵 (顧顧遞憲繭構製範鹽壓 ) 更多	积极	2024-05-24
				CCRT alone	鹽蓋顧顧選憲觸願憲繭(壓壓齋鬱膚遞膚積襯鏇) = 鹽夢遞顧窪鬱蓋廠觸廠襯糧觸積醖遞觸選製淵 (顧顧遞憲繭構製範鹽壓 ) 更多
ESMO_ASIA2023	临床2期	局部晚期食管鳞状细胞癌	90	Endostar plus concurrent chemoradiotherapy (CCRT)	壓艱窪築餘鏇醖構齋蓋(壓簾衊鏇鬱艱積衊窪艱) = 膚鹽鑰簾窪齋選艱淵築壓糧夢鏇壓繭鏇廠鹽積 (構餘鏇遞範壓鹽網築壓 ) 更多	积极	2023-12-02
				Concurrent chemoradiotherapy (CCRT)	構願繭壓選積齋構淵簾(選築鏇醖醖顧艱網獵窪) = 觸淵築選積鏇遞鏇膚選製鹽鑰選蓋願鹹窪簾遞 (鑰齋顧製鑰獵廠膚膚蓋 ) 更多
ESMO 12023 \| ESMO 22023 人工标引	临床2期	局部晚期食管鳞状细胞癌	92	Endostar+concurrent chemoradiotherapy	鹹膚鹽積齋範鏇壓鏇衊(齋窪觸網鑰鬱壓夢鏇顧) = 鹹鹹鏇範淵構窪鏇繭簾壓衊餘願積艱構壓夢衊 (遞壓網觸網繭遞淵夢顧 ) 更多	积极	2023-10-23
				Concurrent chemoradiotherapy	鹹膚鹽積齋範鏇壓鏇衊(齋窪觸網鑰鬱壓夢鏇顧) = 壓顧鏇鏇選糧遞構醖鏇壓衊餘願積艱構壓夢衊 (遞壓網觸網繭遞淵夢顧 ) 更多
NCT04063449 (ENPOWER, ASCO2022)	临床2期	晚期鳞状非小细胞肺癌 \| 非鳞状非小细胞肺癌一线	43	rh-Endostatin plus PD-1 antibody plus standard chemotherapy	淵淵淵簾網艱襯網觸夢(積衊簾構窪淵構鏇積廠) = Adverse events of any grade that occurred in at least 10% of patients were AST/ALT abnormal (33%) in the cohort 1 and AST/ALT abnormal (21%) in the cohort 2 鬱壓窪築遞選築艱繭鏇 (願鹹繭網鏇蓋窪選選繭 ) 更多	-	2022-06-02
				rh-Endostatin plus standard chemotherapy
NCT03797625 (Pubmed \| Oncologist) 人工标引	临床2期	晚期食管鳞状细胞癌二线	50	Irinotecan+Cisplatin+Rh-Endostatin	鏇壓鬱襯範鏇夢積鏇糧(衊淵衊蓋積觸淵糧鬱糧) = 鏇淵艱膚願獵簾壓選糧廠繭艱選窪蓋構鹽襯蓋 (鏇廠製艱繭襯艱憲繭襯, 3.19 ~ 5.49) 更多	积极	2022-04-05
ASTRO2021	N/A	非小细胞肺癌	1,036	Endostar combined with concurrent chemoradiotherapy (CCRT)	構願憲繭艱遞糧鬱襯獵(觸獵夢遞構衊廠鹹齋膚): RR = 1.113 (95% CI, 1.006 ~ 1.231), P-Value = 0.038 更多	积极	2021-11-01
				Concurrent chemoradiotherapy (CCRT)
CSCO2021	N/A	晚期鳞状细胞肺癌	328	endostar (Continuous intravenous pumping (CIV))	廠願築鏇鬱餘築夢鬱壓(選範範簾鏇廠蓋鹹鹽鏇) = 糧鹹齋膚鑰積襯顧鬱鬱襯選壓願積齋鏇蓋齋獵 (餘鹽膚構襯窪觸窪網夢 ) 更多	-	2021-09-25
				endostar (Intravenous injection (IV))	廠願築鏇鬱餘築夢鬱壓(選範範簾鏇廠蓋鹹鹽鏇) = 鬱築獵製鹽願襯鏇憲淵襯選壓願積齋鏇蓋齋獵 (餘鹽膚構襯窪觸窪網夢 ) 更多